Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion

Part of paid clinical trials in Cleveland, Ohio.

Sponsor
Retina Associates of Cleveland, Inc
Study ID
NCT01011374
Phase
PHASE1
Status
Unknown

Conditions

  • Central Retinal Vein Occlusion
  • Depression
  • Retinal Vein Occlusion
  • Venous Retinal Branch Occlusion

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

Study Details

This is a prospective, single-center, non-randomized clinical study on the impact of intravitreally administered ranibizumab (Lucentis) treatment on vision-related functioning and emotional well-being in subjects with central or branch retinal vein occlusion.

Key Dates

First listed
Nov 11, 2009
Start date
Nov 30, 2009
Status verified
Mar 2011
Primary completion
Nov 30, 2012
Completion
Nov 30, 2013

Study Design

Enrollment
45 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Primary Outcome Measure

The primary outcome measures are changes in the VFQ-25, GHQ-12, and PHQ-9 survey scores from baseline through 24 weeks. [ Time Frame: 24 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Retina Associates of ClevelandClevelandOhio44122-

Find similar trials in Cleveland, OH

By condition
Depression
By specialty
PsychiatryMental healthBehavioral health
By research site
Retina Associates of Cleveland· Cleveland, OH

Related Studies